文章：

胃肠道恶性肿瘤中抗HER2疗法的耐药性

Resistance to Anti-HER2 Therapies in Gastrointestinal Malignancies

原文发布日期：15 August 2024

DOI: 10.3390/cancers16162854

类型: Article

开放获取: 是

英文摘要：

Human epidermal growth factor 2 (HER2) is a tyrosine kinase receptor that interacts with multiple signaling pathways related to cellular growth and proliferation. Overexpression or amplification of HER2 is linked to various malignancies, and there have been decades of research dedicated to targeting HER2. Despite the landmark ToGA trial, progress in HER2-positive gastrointestinal malignancies has been hampered by drug resistance. This review examines current HER2 expression patterns and therapies for gastroesophageal, colorectal, biliary tract, and small bowel cancers, while dissecting potential resistance mechanisms that limit treatment effectiveness.

摘要翻译： 

人表皮生长因子受体2（HER2）是一种酪氨酸激酶受体，参与调控细胞生长与增殖相关的多条信号通路。HER2的过表达或扩增与多种恶性肿瘤的发生发展密切相关，针对该靶点的研究已持续数十年。尽管TOGA试验取得了里程碑式突破，但耐药性问题始终制约着HER2阳性胃肠道恶性肿瘤的治疗进展。本文系统综述了当前胃食管癌、结直肠癌、胆道癌及小肠癌中HER2的表达模式与治疗策略，并深入剖析了限制疗效的潜在耐药机制。

原文链接：

Resistance to Anti-HER2 Therapies in Gastrointestinal Malignancies